Calaspargase Pegol
Brand names: Asparlas · Active ingredient: Calaspargase Pegol
In short: ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
What is Calaspargase Pegol used for?
ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Calaspargase Pegol dosage
The recommended dose of ASPARLAS is 2,500 units/m2 given intravenously no more frequently than every 21 days.
Premedicate patients with acetaminophen, an H-1 receptor blocker (such as diphenhydramine), and an H-2 receptor blocker (such as famotidine) 30-60 minutes prior to administration of ASPARLAS to decrease the risk and severity of both infusion and hypersensitivity reactions .
Monitor patients at least weekly with bilirubin, transaminases, glucose, and clinical examinations until recovery from the cycle of therapy. If an adverse reaction should occur, modify treatment according to Table 1.
Adverse Reaction | SeverityGrade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is life-threatening. | Action
Infusion Reaction/ Hypersensitivity Reaction | Grade 1 | Reduce the infusion rate by 50%
Grade 2 | Interrupt the infusion of ASPARLAS
Treat the symptoms
When symptoms resolve, resume the infusion and reduce the infusion rate by 50%
Grade 3 to 4 | Discontinue ASPARLAS permanently
Pancreatitis | Grades 3 to 4 | Hold ASPARLAS for elevations in lipase or amylase >3 × upper limit of normal (ULN) until enzyme levels stabilize or are declining
Discontinue ASPARLAS permanently if clinical pancreatitis is confirmed
Thrombosis | Uncomplicated deep vein thrombosis | Hold ASPARLAS
Treat with appropriate antithrombotic therapy
Upon resolution of symptoms consider resuming ASPARLAS, while continuing antithrombotic therapy
Severe or life-threatening thrombosis | Discontinue ASPARLAS permanently
Treat with appropriate antithrombotic therapy
Hemorrhage | Grade 3 to 4 | Hold ASPARLAS
Evaluate for coagulopathy and consider clotting factor replacement as needed
Resume ASPARLAS with the next scheduled dose if bleeding is controlled
Hepatotoxicity | Total bilirubin more than 3 times to no more than 10 times the ULN | Hold ASPARLAS until total bilirubin is ≤1.5 times the ULN
Total bilirubin more than 10 times the ULN | Discontinue ASPARLAS and do not make up for missed doses
ASPARLAS is a clear and colorless solution. Visually inspect parenteral drug products for particulate matter, cloudiness, or discoloration prior to administration. If any of these are present, discard the vial. Do not administer if ASPARLAS has been shaken or vigorously agitated, frozen, or stored at room temperature for more than 48 hours.
Dilute ASPARLAS in 100 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP using sterile/aseptic technique. Discard any unused portion left in a vial.
After dilution, administer immediately into a running infusion of either 0.9% sodium chloride or 5% dextrose, respectively.
Administer the dose over a period of 1 hour.
Do not infuse other drugs through the same intravenous line during administration of ASPARLAS. …
How to take Calaspargase Pegol — instructions & advice from the label
Hypersensitivity
Inform patients on the possibility of serious allergic reactions, including anaphylaxis. Instruct the patient on the symptoms of allergic reactions and to seek medical advice immediately if they experience such symptoms .
Pancreatitis
Instruct patients on the signs and symptoms of pancreatitis and to seek immediate medical attention if they experience severe abdominal pain .
Instruct patients on the risk of hyperglycemia and glucose intolerance. Advise patients to seek medical advice if they experience excessive thirst or any increase in the volume or frequency of urination .
Thrombosis
Instruct patients on the risk of thrombosis and to seek medical advice immediately if they experience severe headache, arm or leg swelling, shortness of breath, or chest pain .
Hemorrhage
Advise patients to report any unusual bleeding or bruising to their healthcare provider .
Hepatotoxicity , including Veno-Occlusive Liver Disease (VOD)
Inform patients that liver problems, including severe, life-threatening, or fatal VOD and abnormalities in liver tests, may develop during ASPARLAS treatment. …
Warnings & precautions
Do not take this medicine if: ASPARLAS is contraindicated in patients with:
History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
History of serious pancreatitis during previous L-asparaginase therapy
History of serious thrombosis during previous L-asparaginase therapy
History of serious hemorrhagic events during previous L-asparaginase therapy
Severe hepatic impairment
Grade 3 and 4 hypersensitivity reactions, including anaphylaxis, have been reported in clinical trials with ASPARLAS with an incidence between 7 and 21% . Hypersensitivity reactions observed with other asparaginases include angioedema, lip swelling, eye swelling, erythema, blood pressure decreased, bronchospasm, dyspnea, pruritus, and rash .
Premedicate patients 30-60 minutes prior to administration of ASPARLAS . Because of the risk of serious allergic reactions (e.g., life-threatening anaphylaxis), administer ASPARLAS in a clinical setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g., epinephrine, oxygen, intravenous steroids, antihistamines) and observe patients for 1 hour after administration. Discontinue ASPARLAS in patients with serious hypersensitivity reactions.
Cases of pancreatitis have been reported in clinical trials with ASPARLAS with an incidence between 12 and 16% . Hemorrhagic or necrotizing pancreatitis have been reported with other asparaginases.
Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Assess serum amylase and/or lipase levels to identify early signs of pancreatic inflammation. Discontinue ASPARLAS if pancreatitis is suspected; if pancreatitis is confirmed, do not resume ASPARLAS .
Serious thrombotic events, including sagittal sinus thrombosis, have been reported in clinical trials with ASPARLAS with an incidence of 9 to 12%. …
Calaspargase Pegol side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity
Pancreatitis
Thrombosis
Hemorrhage
Hepatotoxicity, including VOD
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Study DFCI 11-001
The safety of ASPARLAS was investigated in Study DFCI 11-001, an open-label, randomized, active-controlled multicenter clinical trial that treated 237 children and adolescents with newly diagnosed ALL or lymphoblastic lymphoma, with ASPARLAS 2,500 U/m2 (n=118) or pegaspargase 2,500 U/m2 (n=119) as part of a Dana-Farber Cancer Institute (DFCI) ALL Consortium backbone therapy. The median age on enrollment was 5 years (range, 1-20 years). The majority of patients were male (62%) and white (70%). Most patients were considered standard risk (SR, 59%) and had B-cell lineage ALL (87%).
The median number of doses during the study was 11 doses for ASPARLAS (administered every three weeks) and 16 doses for pegaspargase (administered every two weeks). The median duration of exposure was 8 months for both ASPARLAS and pegaspargase.
There was 1 fatal adverse reaction (multi-organ failure in the setting of chronic pancreatitis associated with a pancreatic pseudocyst). …
About this medicine
Calaspargase pegol-mknl contains an asparagine specific enzyme derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker. The SC linker is a chemically stable carbamate bond between the mPEG moiety and the lysine groups of L-asparaginase.
L-asparaginase is a tetrameric enzyme that is produced endogenously by E. coli and consists of identical 34.5 kDa subunits. Approximately 31 to 39 molecules of SC-PEG are linked to L-asparaginase; the molecular weight of each SC-PEG molecule is about 5 kDa. The activity of ASPARLAS is expressed in units (U).
ASPARLAS injection is supplied as a clear, colorless, preservative-free, isotonic sterile solution in phosphate-buffered saline, pH 7.3 that requires dilution prior to intravenous infusion. Each vial of ASPARLAS contains 3,750 units in 5 mL of solution. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6585bd0d-bd78-4341-9e87-0f7664821f05. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate